Clinical Trials Directory

Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Stanford is now accepting new patients for this trial. Please contact Lisa Zhou at 650-736-4112 for more information.

Investigator(s):

Intervention(s):

  • procedure : phlebotomy

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

Inclusion Criteria:Inclusion Criteria (Cases): 1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC 2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection 3. ability to sign informed consent 4. at least 18 years of age Inclusion Criteria (Controls): 1. no known prior or active malignancy 2. ability to sign informed consent 3. at least 18 years of age

External Links

Explore related trials

Contact information

Primary Contact:

Lisa Zhou 650-736-4112

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: